-
Biotech Survive Broken Tail! Stone Medicine, Zhongsheng, GSK, BMS, Pfizer throw olive branches! Is it time to dig the bottom?
Time of Update: 2022-10-25
01 Go in both directions, each take what you need Biotech joins hands with Big Pharma to survive the winter On April 1 this year, Nature Reviews Drug Discovery published a statistical article on the field of innovative drugs in China, and the content analysis pointed out that as of July 1, 2021, there were 2,251 drugs (including drugs and biological products) under development in all therapeutic areas in China, including 418 first-in-class, 473 fast-follower, and 923 me-too.
-
Global medicine news GSK/Sanofi new crown vaccine "2.0 version" enters Phase 2 clinical trial, AbbVie JAK inhibitor Phase 3 clinical success
Time of Update: 2021-07-25
On February 22, local time, Sanofi and GlaxoSmithKline (GSK) jointly announced that after adjustments, the new version of the adjuvant-based recombinant protein-based new coronary pneumonia (COVID-19) vaccine jointly developed by the two parties entered Phase 2 clinical trials.
-
Breathe new medicine! GSK single inhaler triple therapy Trelegy Ellipta has been approved by the European Union to expand chronic pulmonary estration
Time of Update: 2021-02-14
British pharmaceutical giant GlaxoSmithKline (GSK) and partner Innoviva recently announced that the European Commission (EC) has approved an extension of the triple therapy Trelegy Ellipta (FF/UMEC/VI) label for chronic obstructive pulmonary disease (COPD) Treatment of patients, specifically: receiving a double bronchid dilate or an inhaled corticosteroid (ICS) and a long-acting beta-2 astration (LABA) in a combined treatment of moderate to severe COPD patients who did not adequately control the condition.
-
GSK sets up APVC Fund to invest in bio-electronic medicine
Time of Update: 2020-06-03
Business Agency, August 9 (GSK) today announced the establishment of the APVC Fund (Action Venture Capital), a new $50 million strategic venture capital fund that will invest in bioelectronics phar
-
Hengruihua takes the first endocrine medicine, imitates Zhengda Tianqing and grabs GSK anti asthma medicine
Time of Update: 2019-07-11
Medical network, July 11 news, July 10, Hengrui pharmaceutical released a notice that its subsidiary Chengdu Shengdi pharmaceutical recently received the approval of drug registration issued by the St
-
[yaocajun] it is the best-selling generic medicine in China that has passed Hengrui
Time of Update: 2019-07-08
Highlights: 1 Novartis 20 billion market power MS drug will be in the future; 1 The first drug approved by FDA in 56 years, the heavy-duty lupus erythematosus monoclonal antibody will be listed in Chi
-
GSK joins hands with apple research kit to enter the era of personalized "medicine making"
Time of Update: 2015-07-15
Source: bioprospecting 2015-7-15 according to the latest news from firstword Pharma, GSK and Purdue Pharma will use Apple's Research Kit framework for drug research and development, which is the first
-
Novartis: US $16 billion acquisition of GSK's cancer medicine business
Time of Update: 2015-05-05
Source: Tencent finance 2015-5-5 according to Bloomberg, Novartis agreed to buy GlaxoSmithKline's cancer drug business for up to $16 billion, set up a consumer healthcare joint venture with GlaxoSmith
-
2014 access to medicine index: GSK topped the list four times
Time of Update: 2014-11-19
Source: bioprospecting 2014-11-19 in the world of more than 7 billion people, 2 billion people still can't afford drugs To this end, there are charities to assess and improve the status quo Each year,
-
Apollo plans to acquire GSK's patent expired medicine business
Time of Update: 2014-11-18
Source: Biovalley 2014-11-18 as the patent cliff approaches, many biopharmaceutical companies have to face the siege of the best-selling drugs they develop from cheap generic drugs It is also this opp
-
GSK establishes APVC fund to invest in the field of bio electronic medicine
Time of Update: 2013-08-09
Source: on August 9, 2013, GlaxoSmithKline announced the establishment of APVC Fund (action potential venture capital), a new $50 million strategic venture fund, which will invest in the pioneers in t